Concepedia

Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration

Gui‐Shuang Ying, Jiayan Huang, Maureen G. Maguire, Glenn J. Jaffe, Juan E. Grunwald, Cynthia A. Toth, Ebenezer Daniel, Michael L. Klein, Dante J. Pieramici, John A. Wells,

Ophthalmology · 2012 · 310 citations · 12 references

DOIFull text

Open access

Concepts

References

12

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

, , +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

, , +13

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine · 2011 · 2.6K citations · Full text

, , +12

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Robert L. Avery, Dante J. Pieramici, Melvin Rabena et al. · Ophthalmology · 2006 · 1.1K citations

, , +14

Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, Andrew A. Moshfeghi, Carmen A. Puliafito · Ophthalmic surgery, lasers & imaging retina · 2005 · 907 citations

, , +17